



FOR IMMEDIATE RELEASE

Press Inquires: Nicole Naviglia
Phone: (336) 448-0718
Email: nicole@commongiant.com

New Test Helps Diagnose Pediatric Sleep Disorder Often Mistaken for ADHD

Innovator of Easy Peezy Pee Test says nearly 3.5 million kids diagnosed with ADHD may actually have Obstructive Sleep Apnea.

SEVERNA PARK, Md. (September 10, 2014) – An innovative new diagnostic test in development at NuSomnea has been found to be 96.5% accurate in determining if a child has pediatric Obstructive Sleep Apnea, or OSA. This condition is associated with symptoms often mistaken for Attention Deficit/Hyperactivity Disorder, or ADHD.

The aptly named [Easy Peezy Pee Test](#) identifies the urinary concentrations of four proteins that are predictive of pediatric OSA, representing a remarkable improvement over traditional, and costly, diagnostic methods. “Diagnosing OSA usually requires an expensive stay at a sleep lab. It’s inconvenient for parents and uncomfortable for kids,” said Michael Thomas, co-founder of NuSomnea. “We’re changing that with a simple urine test that’s more accessible, more accurate and costs about seventy-five percent less.”

Obstructive sleep apnea is a common sleep disorder resulting from the collapse of the pharyngeal airway during sleep, often hundreds of times per night, depleting blood oxygen saturation and contributing to a host of serious health problems. Pediatric OSA is linked to a greater incidence of childhood obesity, asthma, nervous conditions and bed-wetting. Left untreated, pediatric OSA can lead to hypertension, cardiovascular disease and diabetes as children grow older. While OSA is usually associated with adults, research shows that 2-5% of children have pediatric OSA, and it is a growing problem in the US.

Snoring is one of the indicators that a child may have OSA. Studies have reported that 27% of children snore and it can be difficult for doctors to determine from a medical exam alone which patients should be tested for OSA.

In children, other common indicators of OSA are behavioral problems, learning disabilities, hyperactivity and attention problems, which may frequently be diagnosed as ADHD or ADD. Nearly 7 million children between 4 and 17 years old are currently diagnosed with ADHD, but research has reported that up to 50% might actually have pediatric OSA. Further, a large percentage of kids with ADHD respond to the standard treatment for OSA – tonsil and adenoid surgery – reinforcing the conclusion that many have OSA in addition to or instead of ADHD. If a child has OSA, treating only for ADHD with stimulant drugs may not resolve the issue.

Because the [Easy Peezy Pee Test](#) is so convenient to administer, it has the potential to be used as both a diagnostic tool and a disease management tool to more closely monitor therapy effectiveness and improve patient outcomes.

The [Easy Peezy Pee Test](#) by NuSomnea is still in clinical development and is not currently available. On September 16, 2014, NuSomnea will launch an Indiegogo fundraising campaign to help complete the development of the urinalysis test and to conduct a validation study in children, to confirm the results found in initial studies.

NuSomnea hopes to have the Easy Peezy Pee Test available to doctors by 2016.

Visit www.easypeezytest.com to learn more.

About NuSomnea

NuSomnea is committed to finding better ways to identify people at risk for Obstructive Sleep Apnea – a dangerous and costly disorder for children and adults – and enhance their treatment success. Our executive team has been at the forefront of innovation in both sleep lab and home sleep testing and is now developing an accurate, easier, and less expensive advancement for the detection of sleep apnea in children. The Easy Peezy Pee Test is an assay of multiple urinary peptide biomarkers which, when measured at certain levels, have been shown to be highly predictive of sleep apnea. When the development is completed and validated, this method will allow children to be diagnosed with a morning urine sample, rather than an overnight polysomnograph study in a sleep lab.

Our co-founding partner, [PGXL Laboratories](#), is an internationally recognized pioneer in personalized medicine through the application of molecular diagnostics to pharmacogenetics and is the first laboratory to be CLIA-certified for pharmacogenetic testing.

Please visit www.nusomnea.com for more information.